Menu
Search
|

Menu

Close
X

Zhejiang Jiuzhou Pharmaceutical Co Ltd 603456.SS (Shanghai Stock Exchange)

9.00 CNY
+0.08 (+0.90%)
As of 8:00 AM BST
Previous Close 8.92
Open 8.90
Volume 3,092,200
3m Avg Volume 4,953,193
Today’s High 9.02
Today’s Low 8.80
52 Week High 10.50
52 Week Low 5.50
Shares Outstanding (mil) 447.85
Market Capitalization (mil) 7,161.06
Forward P/E 48.09
Dividend (Yield %) 0.10 ( 0.63 )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.00 Mean rating from 3 analysts

KEY STATS

Revenue (mm, CNY)
FY19
398
FY18
1,862
FY17
1,717
FY16
1,653
EPS (CNY)
FY19
0.054
FY18
0.195
FY17
0.185
FY16
0.140
*Note: Units in Millions of Renminbi
**Note: Units in Renminbi

KEY RATIOS

Price to Earnings (TTM)
vs sector
48.09
300.40
Price to Sales (TTM)
vs sector
4.23
12.02
Price to Book (MRQ)
vs sector
2.77
2.82
Price to Cash Flow (TTM)
vs sector
--
14.86
Total Debt to Equity (MRQ)
vs sector
5.92
41.40
LT Debt to Equity (MRQ)
vs sector
0.00
30.90
Return on Investment (TTM)
vs sector
5.65
11.06
Return on Equity (TTM)
vs sector
5.79
14.01

EXECUTIVE LEADERSHIP

Lirong Hua
Chairman of the Board, Since 2016
Salary: --
Bonus: --
Zhihong Chen
General Manager, Since 2016
Salary: --
Bonus: --
Huilu Lin
Deputy General Manager, Secretary of the Board, Since
Salary: --
Bonus: --
Daqing Che
Deputy General Manager, Since
Salary: --
Bonus: --
Zulin Jiang
Deputy General Manager, Since
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Basic Materials
Industry: Specialty Chemicals
Address:

No.99, Waisha Road, Jiaojiang Di
TAIZHOU   ZHJ   318000

Phone: +86576.88706789

Zhejiang Jiuzhou Pharmaceutical Co.,Ltd. is a China-based company principally engaged in the research, development, production and sales of chemical Active Pharmaceutical Ingredients (API) and intermediates. The Company mainly operates through two segments, including the New Drug and Intermediates Contract Development and Manufacturing Organization (CDMO) segment and the Specialty APIs and Intermediates segment. The New Drug and Intermediates CDMO segment mainly provides services for innovative medicines of pre-clinical chemical manufacturing and controls (CMC), clinical phases I, II and III, new drug application (NDA) and various stages after going public. The Specialty API and Intermediates segments mainly provides services including patent breakthroughs, production process improvement, drug certificate declaration, and cGMP standard commercial production for patented expired or soon-to-be-expired drugs for global chemical and generic drug manufacturers.

SPONSORED STORIES